Literature DB >> 32910702

Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis.

Edgar Carnero Contentti1, Jorge Correale2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32910702     DOI： 10.1080/14728214.2020.1822817

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN： 1472-8214            Impact factor:   4.191


× No keyword cloud information.
  9 in total

Review 1.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 2.  Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Authors:  George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 3.  The Development of BTK Inhibitors: A Five-Year Update.

Authors:  Bruno Tasso; Andrea Spallarossa; Eleonora Russo; Chiara Brullo
Journal:  Molecules       Date:  2021-12-06       Impact factor: 4.411

Review 4.  Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.

Authors:  Monica Margoni; Paolo Preziosa; Massimo Filippi; Maria A Rocca
Journal:  J Neurol       Date:  2021-08-11       Impact factor: 6.682

Review 5.  A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.

Authors:  Laurent Monassier; Ayikoé Guy Mensah-Nyagan; Nicolas Collongues; Guillaume Becker; Valérie Jolivel; Estelle Ayme-Dietrich; Jérôme de Seze; Fabien Binamé; Christine Patte-Mensah
Journal:  Neurol Ther       Date:  2022-05-24

6.  Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.

Authors:  Liza Rijvers; Jamie van Langelaar; Laurens Bogers; Marie-José Melief; Steven C Koetzier; Katelijn M Blok; Annet F Wierenga-Wolf; Helga E de Vries; Jasper Rip; Odilia Bj Corneth; Rudi W Hendriks; Roland Grenningloh; Ursula Boschert; Joost Smolders; Marvin M van Luijn
Journal:  JCI Insight       Date:  2022-08-22

Review 7.  Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

Authors:  Anastasia Geladaris; Sebastian Torke; Martin S Weber
Journal:  CNS Drugs       Date:  2022-09-30       Impact factor: 6.497

Review 8.  Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.

Authors:  Edgar Carnero Contentti; Jorge Correale
Journal:  Drug Des Devel Ther       Date:  2022-10-06       Impact factor: 4.319

Review 9.  Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.

Authors:  Pedro Mendes-Bastos; Ana Brasileiro; Pavel Kolkhir; Stefan Frischbutter; Jörg Scheffel; Sherezade Moñino-Romero; Marcus Maurer
Journal:  Allergy       Date:  2022-02-28       Impact factor: 14.710
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.